Microgravity drug crystallization and formulation: Junction Brief – November 2026

Acentric Research is produced with AI tools under human review. The authors are not financial professionals, and nothing here is investment advice or a recommendation to buy or sell any security. AI analysis can be wrong; check every claim against its cited source.

This Brief is an initial scan, not a full investigation. The method and scores behind it are in Biotechnology × Space in the Landscape Report.

Overview

A trade article says about 90% of small-molecule medicines for common ailments are formed as crystals, and that the structure and purity of the crystals can affect how a drug is given to a patient. [1] It adds that previous space research has shown crystals often grow more uniformly and with fewer imperfections without gravity. The ISS National Laboratory says microgravity has been used for more than 30 years to improve the growth of molecular crystals, with uses in drug development, agriculture, optics and electronics. [2] Researchers now fly drug crystals to the International Space Station (ISS) and bring them back.

What stands out is that this has moved from a research idea to repeated company-run flights, but without a reported product. Redwire says it has processed 16 units of its crystal platform, and that insulin crystals grown in orbit in a study with Eli Lilly were larger and more ordered than those grown on Earth; the release gives no measurements. [3] None of the sources opened reports a medicine made with a space-grown crystal; ClinicalTrials.gov and FDA records were not searched. The sources date from 2023 and 2024, plus two undated programme pages, and later developments were not searched.

Current state

What the technology does. A drug crystal grown in orbit is returned to Earth and studied. Redwire developed a platform it calls the Pharmaceutical In-space Laboratory (PIL) Bio-crystal Optimization eXperiment, or PIL-BOX, which mixes solutions from sealed bags to form crystals; a trade article says it can support 10 experiments at a time. [1] Redwire says its system has an integrated microscope that watches crystals form and gives researchers data for drug discovery and for improving existing products. [3] The company says the first investigation with Lilly launched in November 2023, and that a second investigation grew the same insulin samples again to show consistent, repeatable results. [3]

Who is working on it. Redwire describes itself as a global space infrastructure and innovation company. [3] Its release says Eli Lilly and Company researchers use the experiment to potentially speed the discovery of medicines for chronic diseases. It says 12 more units launched in 2024 for new partners Bristol Myers Squibb and ExesaLibero Pharma, along with a second investigation with Butler University, and that earlier investigations covered crystals for cardiovascular disease, obesity and diabetes treatments. [3] The first experiment was ISS National Laboratory-sponsored and awarded through a NASA in-space production solicitation. [1]

In Europe, the European Space Agency's Business and Science Growth Network runs a life sciences industry accelerator that offers co-funding and support to biotechnology, pharmaceutical and cosmetics projects that use space, including access to microgravity research facilities and links to commercial space partners. [4] The accelerator's page describes BioOrbit (UK), which aims to develop an orbital platform for large-scale production of crystalline protein therapeutics, starting with monoclonal antibodies; it says the accelerator co-funded a flight of protein samples and that an in-orbit demonstration is scheduled for 2027 (the project's aim, as the page states it). [4] Redwire's chief scientist says the platform will cycle through different conditions and samples to see whether crystals grow in its bags. [1]

How far it has come. Experiments have flown on the ISS several times, according to the company. Three batches of crystals have returned to Earth, according to the company. [3] The sources opened report no medicine or formulation made with an in-space crystal, and the company release gives no measurements of crystal size or order, so the result is stated as the company reports it. [3]

Opportunities

Redwire's chief scientist says seeds grown in space could be brought back and used to grow more crystals on Earth, so that only a small amount, "maybe a thimbleful", needs to fly. This is a company statement of intent. [1] The ISS National Laboratory says its production programme aims to help projects cross the gap between laboratory discovery and a product, and describes its programme as seeking projects with "the potential to generate demand for and revenue from access to space". [2] The ISS National Laboratory also says it wants projects in this area to inform new classes of materials and products. [2] Redwire (company release) says Lilly will use its second investigation's findings to widen its understanding of how crystal formation affects drug discovery and development. [3]

Challenges

  • Physics and engineering. Each flight carries small amounts of material and must be launched and returned to Earth, and the results so far are crystal quality, not a drug. A company statement says the aim is repeatable, scalable results; the release gives no yield or cost figures. [3][1]
  • Capital and scale-up. The sources opened give no price for a flight or a crystal. Funding comes in part from NASA and the ISS National Laboratory, as the Redwire release thanks them for support. [3]

Data sources

  • ISS National Laboratory programme pages and project portfolio, for sponsored flights. [5]
  • Company press releases and SEC filings (Redwire's investor site, EDGAR), for flights and partners; EDGAR was not searched for this Brief. [3][6]
  • ClinicalTrials.gov, for any study of a product linked to space-grown crystals. [7]
  • No registry of in-space crystallization results was found; company releases are the main record.

Changelog

  • 2026-11-18: First published.

Sources

  1. Manufacturing Chemist, "Redwire's Lab-in-a-Box aims to leverage the ISS National Lab to improve drug manufacturing" (trade article, published 2023-11-17; it describes the SpaceX CRS-29 launch; statements by the company's chief scientist are the company's). manufacturingchemist.com (accessed 2026-11-18)
  2. ISS National Laboratory, "In-Space Production Applications" (programme page, undated; statements about the programme and about microgravity research are the Laboratory's). issnationallab.org (accessed 2026-11-18)
  3. Redwire Corporation, "Redwire Successfully Returns Third Batch of Pharmaceutical Drug Experiments to Earth", 2024-11-06 (company press release; the results and plans are the company's). ir.rdw.com (accessed 2026-11-18)
  4. European Space Agency, Business and Science Growth Network (BSGN), "Life Sciences Industry Accelerator" (programme page, undated). bsgn.esa.int (accessed 2026-11-18)
  5. ISS National Laboratory, research project portfolio. issnationallab.org (listed as a data source; the portfolio itself was not opened for this Brief)
  6. SEC EDGAR, full-text search. sec.gov (listed as a data source; not run for this Brief)
  7. ClinicalTrials.gov, study search. clinicaltrials.gov (listed as a data source; not searched for this Brief)